Saturday, March 3, 2018
Marriott Copley Place
BOSTON
Plenary Session 1; Current Status of Existing Technologies:
Charles Flexner, Johns Hopkins University
Welcome! Where will we LEAP to next?! Overview of Workshop
[audio-only/slide]
Peter Williams (Janssen)
Current Status of Clinical Development of LA-Rilpivirine?
[audio-only/slide]
William Spreen, (ViiV Healthcare)
Current Status of Clinical Development of LA-Cabotegravir
[audio-only/slide]
Jay Grobler, Merck
Current Status of the Merck LA/ER Pipeline
[audio-only/slide]
Question and Answer for Jay, William, and Bill
[audio-only/slide]
Susan Swindells, University of Nebraska Medical Center
LEAP TB – Update from the LEAP Working Group on Development of Long-Acting Approaches to the Treatment of Tuberculosis
[audio-only/slide]
Marco Siccardi, University of Liverpool (being presented by Andrew Owen)
Update from the LEAP Modeling and Simulation Core: The use of Physiologicallybased Pharmacokinetic and Pharmacodynamic Modelling to
Assess Drug Candidates
[audio-only/slide]
Polly Clayden, iBase
Summary of the November, 2017 Workshop on Long Acting/Extended Release Antiretroviral Formulations for HIV Treatment and Prevention
in Children, Adolescents, and PregnantWomen: Knowledge Gaps and Approaches for Development
[audio-only/slide]
Plenary Session 2; Novel approaches to LA/ER Drug Delivery: 10-Minute Presentations followed by Five-Minute Q & A:
Leah Johnson, RTI International (presented by Ariane van der Straten)
Biodegradable Implants for PreP
[audio-only/slide]
Ryan Donnelly, University of Belfast
LA ART Transdermal Delivery Using Microneedle Technology
[audio-only/slide]
Rodney Ho, University of Washington
Phase 0 Development of Combination LA ART Delivered Subcutaneously
[audio-only/slide]
Andrew Owen, University of Liverpool
Nanoformulation of novel NRTI prodrugs
[audio-only/slide]
David Thomas, Johns Hopkins University
LA Drugs for HCV Eradication: Time to Reconsider?
[audio-only/slide]
FOCUS GROUPS' FEEDBACK:
GROUP 1: Craig Hendrix, Rapporteur
Phase 0 and microdosing as a strategy for efficient development of LA-ER formulations
[audio-only/slide]
GROUP 2: Polly Clayden, Rapporteur
Managing drug toxicities, co-morbidities, and drug-drug interactions in the context of LA/ER
[audio-only/slide]
GROUP 3: Paul Domanico, Rapporteur (being presented by Trip Gulick)
Streamlining development of investigational drugs and novel prodrugs for LA-ER formulation and clinical development
[audio-only/slide]
GROUP 4: Charles Boucher, Rapporteur
Monitoring and Managing Drug Resistance: What kind of monitoring needs to be done in the real world setting?
[audio-only/slide]
GROUP 5: Marco Siccardi, Rapporteur (being presented by Andrew Owen)
LA/ER Development for Tuberculosis
[audio-only/slide]